Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0000237
UniProt IDQ07817
Primary gene name(s)BCL2L1
Synonym gene name(s)BCL2L, BCLX
Protein nameBcl-2-like protein 1
Protein functionPotent inhibitor of cell death. Inhibits activation of caspases. Appears to regulate cell death by blocking the voltage-dependent anion channel, VDAC by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. Also acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis.; FUNCTION: Isoform Bcl-X(L also regulates presynaptic plasticity, including neurotransmitter release and recovery, number of axonal mitochondria as well as size and number of synaptic vesicle clusters. During synaptic stimulation, increases ATP availability from mitochondria through regulation of mitochondrial membrane ATP synthase F(1F(0 activity and regulates endocytic vesicle retrieval in hippocampal neurons through association with DMN1L and stimulation of its GTPase activity in synaptic vesicles. May attenuate inflammation impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release, PubMed:17418785. {ECO:0000269|PubMed:17418785}.; FUNCTION: Isoform Bcl-X(S promotes apoptosis.
Subcellular locationIsoform Bcl-X(L: Mitochondrion inner membrane {ECO:0000250}. Mitochondrion outer membrane {ECO:0000250}. Mitochondrion matrix {ECO:0000250}. Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane {ECO:0000250}. Cytoplasm, cytosol {ECO:0000250}. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Nucleus membrane {ECO:0000250};
Single-pass membrane protein {ECO:0000250};
Cytoplasmic side {ECO:0000250}. Note=After neuronal stimulation, translocates from cytosol to synaptic vesicle and mitochondrion membrane in a calmodulin-dependent manner, By similarity. Localizes to the centrosome when phosphorylated at Ser-49. {ECO:0000250}.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: Q07817
Gene Ontology
(Biological Process)
Complete annatation
apoptotic mitochondrial changes [GO:0008637];
apoptotic process in bone marrow [GO:0071839];
cell proliferation [GO:0008283];
cellular process regulating host cell cycle in response to virus [GO:0060154];
cellular response to alkaloid [GO:0071312];
cellular response to amino acid stimulus [GO:0071230];
cellular response to gamma radiation [GO:0071480];
cytokinesis [GO:0000910];
endocytosis [GO:0006897];
extrinsic apoptotic signaling pathway in absence of ligand [GO:0097192];
fertilization [GO:0009566];
germ cell development [GO:0007281];
growth [GO:0040007];
hepatocyte apoptotic process [GO:0097284];
intrinsic apoptotic signaling pathway in response to DNA damage [GO:0008630];
in utero embryonic development [GO:0001701];
male gonad development [GO:0008584];
mitochondrion morphogenesis [GO:0070584];
mitotic cell cycle checkpoint [GO:0007093];
negative regulation of anoikis [GO:2000811];
negative regulation of apoptotic process [GO:0043066];
negative regulation of autophagy [GO:0010507];
negative regulation of establishment of protein localization to plasma membrane [GO:0090005];
negative regulation of execution phase of apoptosis [GO:1900118];
negative regulation of extrinsic apoptotic signaling pathway in absence of ligand [GO:2001240];
negative regulation of intrinsic apoptotic signaling pathway [GO:2001243];
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage [GO:1902230];
negative regulation of neuron apoptotic process [GO:0043524];
negative regulation of release of cytochrome c from mitochondria [GO:0090201];
neuron apoptotic process [GO:0051402];
ovarian follicle development [GO:0001541];
positive regulation of cell proliferation [GO:0008284];
positive regulation of intrinsic apoptotic signaling pathway [GO:2001244];
regulation of mitochondrial membrane permeability [GO:0046902];
regulation of mitochondrial membrane potential [GO:0051881];
release of cytochrome c from mitochondria [GO:0001836];
response to cycloheximide [GO:0046898];
response to cytokine [GO:0034097];
spermatogenesis [GO:0007283];
suppression by virus of host apoptotic process [GO:0019050]
Gene Ontology
(Molecular Function)
Complete annatation
BH3 domain binding [GO:0051434];
identical protein binding [GO:0042802];
protein heterodimerization activity [GO:0046982];
protein homodimerization activity [GO:0042803];
protein kinase binding [GO:0019901]
Gene Ontology
(Cellular Component)
Complete annatation
Bcl-2 family protein complex [GO:0097136];
cell junction [GO:0030054];
centrosome [GO:0005813];
cytoplasm [GO:0005737];
cytosol [GO:0005829];
integral component of membrane [GO:0016021];
mitochondrial inner membrane [GO:0005743];
mitochondrial matrix [GO:0005759];
mitochondrial outer membrane [GO:0005741];
mitochondrion [GO:0005739];
nuclear membrane [GO:0031965];
synaptic vesicle membrane [GO:0030672]
Protein-protein interaction107070
Phylogenetic treeQ07817
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
      unknown
Brass et al., Science, 2008
      unknown
Smith et al., J. Immunol, 2010
      unknown
Interferon-stimulated
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model


DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD33.2741195651429800
AZA vs. DISU-0.2410071914205080.3410331202379370.880262543573058
AZA vs. IL70.0351592194990050.8550581938607590.999311006273513
AZA vs. SAHA-0.4131306473093340.09135364932895570.380089679819122
DISU vs. CD3-3.5262095942404400
DISU vs. IL70.265997010396040.2914183609868760.676969599912246
DISU vs. SAHA-0.1697232684707210.5606558814064870.856267205986741
DMSO vs. AZA-0.009157975369724990.9564882903855011
DMSO vs. CD3-3.2933056330427400
DMSO vs. DISU0.2302508331637740.3456601905304480.841126928999491
DMSO vs. IL70.05152611711476830.77466444372640.953700815775867
DMSO vs. SAHA-0.4092207825158490.08335440417195850.336341158038979
HIV vs. Mock in Activation0.268745065592120.6654679331368110.999983755607037
HIV vs. Mock in Latency-0.115621862580980.6932098583514750.999834320637052
IL7 vs. CD3-3.2339960476638100
SAHA vs. CD3-3.7098956093731300
SAHA vs. IL7-0.4498258337507790.06539002657497310.219199531081816
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) FALSE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK -0.424977 0.000305467
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
1.081 1.026 1.217 1.232 1.208
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB07108 4&,39;-FLUORO-1,1&,39;-BIPHENYL-4-CARBOXYLIC ACID experimental unknown unknown

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1BXL NMR - A=1-209.
1G5J NMR - A=1-209.
1LXL NMR - A=1-209.
1MAZ X-ray 2.2Å A=1-209.
1R2D X-ray 1.9Å A=1-211.
1R2E X-ray 2.1Å A=1-211.
1R2G X-ray 2.7Å A=1-211.
1R2H X-ray 2.2Å A=1-211.
1R2I X-ray 2.0Å A=1-211.
1YSG NMR - A=1-209.
1YSI NMR - A=1-209.
1YSN NMR - A=1-209.
2B48 X-ray 3.4Å A=1-211.
2LP8 NMR - A=1-209.
2LPC NMR - A=1-209.
2M03 NMR - A=1-209.
2M04 NMR - A=1-209.
2ME8 NMR - A=1-209.
2ME9 NMR - A=1-209.
2MEJ NMR - A=1-209.
2O1Y NMR - A=1-209.
2O2M NMR - A=2-20# A=83-196.
2O2N NMR - A=2-20# A=83-196.
2P1L X-ray 2.5Å A/C/E/G=1-209.
2PON NMR - B=1-196.
2YJ1 X-ray 2.2Å A/C=1-209.
2YQ6 X-ray 1.8Å A=1-209.
2YQ7 X-ray 1.9Å A=1-209.
2YXJ X-ray 2.2Å A/B=1-209.
3CVA X-ray 2.7Å X=1-211.
3FDL X-ray 1.7Å A=1-209.
3FDM X-ray 2.2Å A/B/C=1-209.
3INQ X-ray 2.0Å A/B=1-209.
3IO8 X-ray 2.3Å A/C=1-209.
3PL7 X-ray 2.6Å A/B=1-209.
3QKD X-ray 2.0Å A/B=1-209.
3R85 X-ray 1.9Å A/B/C/D=1-197.
3SP7 X-ray 1.4Å A=1-209.
3SPF X-ray 1.7Å A=1-209.
3WIZ X-ray 2.4Å A/B=1-209.
3ZK6 X-ray 2.4Å A/B=1-209.
3ZLN X-ray 2.2Å A=1-209.
3ZLO X-ray 2.6Å A=1-209.
3ZLR X-ray 2.0Å A/B=1-209.
4A1U X-ray 1.5Å A=1-209.
4A1W X-ray 2.5Å A/B/C/D=1-209.
4AQ3 X-ray 2.4Å A/B/C/D/E/F=29-44.
4BPK X-ray 1.7Å A/B=1-209.
4C52 X-ray 2.0Å A/B=1-209.
4C5D X-ray 2.3Å A/B=1-209.
4CIN X-ray 2.6Å A/B=1-209# C/D=79-102.
4EHR X-ray 2.0Å A=1-209.
4HNJ X-ray 2.9Å A/B=1-209.
4IEH X-ray 2.1Å A=29-44.
4PPI X-ray 2.8Å A=1-209.
4QVE X-ray 2.0Å A=1-209.
4QVF X-ray 1.5Å A=1-209.
4QVX X-ray 2.1Å A/B=1-23# A/B=83-209.
4TUH X-ray 1.8Å A/B/C/D/E/F/G/H=1-209.
4Z9V X-ray 2.1Å A/B=1-208.
5AGW X-ray 2.6Å A/B=29-44.
5AGX X-ray 2.2Å A/B=29-44.
5C3G X-ray 2.4Å A=83-209.
5FMJ X-ray 2.4Å A=1-209.
5FMK X-ray 1.7Å A=1-209.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Vpr interacts with 22403404
nucleocapsid downregulates 18051367
Envelope surface glycoprotein gp120 downregulates 23382671
Envelope surface glycoprotein gp160; precursor interacts with 11739707
Envelope surface glycoprotein gp120 interacts with 17457084
18220834
Vpr downregulates 11437653
1822083422552851
Nef downregulates 11123279
18220834
Tat upregulates 11994280
18220834
Vpu downregulates 11696595
18220834
Vpr relocalizes 10713718
Nef upregulates 15459189

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa01521 EGFR tyrosine kinase inhibitor resistance - Homo sapiens (human)
hsa01524 Platinum drug resistance - Homo sapiens (human)
hsa04014 Ras signaling pathway - Homo sapiens (human)
hsa04064 NF-kappa B signaling pathway - Homo sapiens (human)
hsa04151 PI3K-Akt signaling pathway - Homo sapiens (human)
hsa04210 Apoptosis - Homo sapiens (human)
hsa04215 Apoptosis - multiple species - Homo sapiens (human)
hsa04621 NOD-like receptor signaling pathway - Homo sapiens (human)
hsa04630 Jak-STAT signaling pathway - Homo sapiens (human)
hsa05014 Amyotrophic lateral sclerosis (ALS) - Homo sapiens (human)
hsa05145 Toxoplasmosis - Homo sapiens (human)
hsa05166 HTLV-I infection - Homo sapiens (human)
hsa05200 Pathways in cancer - Homo sapiens (human)
hsa05202 Transcriptional misregulation in cancer - Homo sapiens (human)
hsa05212 Pancreatic cancer - Homo sapiens (human)
hsa05220 Chronic myeloid leukemia - Homo sapiens (human)
hsa05222 Small cell lung cancer - Homo sapiens (human)
Menu